Laboratory of Biorecognition Chemistry, Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University, Katsura, Nishikyo-ku, Kyoto, 615-8510, Japan.
Department of Cellular Regulation, Research Institute for Microbial Diseases, Osaka University, Suita, 565-0871, Osaka, Japan.
Sci Rep. 2024 Oct 25;14(1):25432. doi: 10.1038/s41598-024-76269-1.
Phosphatase of regenerating liver (PRL) is an oncogenic protein that promotes tumor progression by directly binding to cyclin M (CNNM) membrane proteins and inhibiting their Mg efflux activity. In this study, we have developed a high-throughput screening system to detect the interactions between PRL and CNNM proteins based on homogenous time-resolved fluorescence resonance energy transfer (HTR-FRET, HTRF). We optimized the tag sequences attached to the recombinant proteins of the CNNM4 CBS domains and PRL3 lacking the carboxyl terminal CAAX motif, and successfully detected the interaction by observing the FRET signal in the mixture of the tagged proteins and fluorophore-conjugated antibodies. Moreover, we performed compound library screening using this system and discovered several compounds that could efficiently inhibit the PRL-CNNM interaction. Characterization of one candidate compound revealed that it was relatively stable compared with thienopyridone, a known inhibitor of the PRL-CNNM interaction. The candidate compound can also inhibit PRL function in cells: suppression of CNNM-dependent Mg efflux, and has sufficient in vitro drug metabolism and pharmacokinetic properties. Overall, these results demonstrate the effectiveness of this screening system for identifying novel inhibitors of the PRL-CNNM interaction, which could contribute to the development of novel anti-cancer drugs.
肝再生磷酸酶(PRL)是一种致癌蛋白,通过直接与细胞周期蛋白 M(CNNM)膜蛋白结合并抑制其镁流出活性,促进肿瘤进展。在这项研究中,我们开发了一种基于均相时间分辨荧光共振能量转移(HTR-FRET,HTRF)的高通量筛选系统,用于检测 PRL 和 CNNM 蛋白之间的相互作用。我们优化了连接到 CNNM4 CBS 结构域和缺乏羧基末端 CAAX 基序的 PRL3 的重组蛋白的标签序列,并通过观察标记蛋白和荧光素缀合抗体混合物中的 FRET 信号,成功检测到相互作用。此外,我们使用该系统进行了化合物文库筛选,并发现了几种可有效抑制 PRL-CNNM 相互作用的化合物。对一种候选化合物的表征表明,与已知的 PRL-CNNM 相互作用抑制剂噻吩并吡啶相比,它具有相对稳定性。候选化合物还可以抑制细胞中的 PRL 功能:抑制 CNNM 依赖性镁流出,并且具有足够的体外药物代谢和药代动力学特性。总体而言,这些结果表明该筛选系统可有效识别 PRL-CNNM 相互作用的新型抑制剂,这可能有助于开发新型抗癌药物。